The American group Johnson & Johnson today announced a net profit of 12,255 million dollars in the first nine months of the year, 2% more than in the same period of the previous year.
The company based in New Brunswick (New Jersey) made until September a profit of $ 4.49 per share, compared to $ 4.37 a year ago.
If extraordinary charges are discounted, Johnson & Johnson earned $ 16,943 million or $ 6.21 per share between January and September, a year-on-year increase of 11%.
The turnover of Johnson & Johnson amounted to 61,187 million dollars in the first nine months of the year, an increase of 8.8% and was above the expectations of analysts, thanks mainly to an increase in product sales pharmacists
In the third quarter, data to which investors paid more attention today, the company invoiced 20,348 million dollars and had a net profit of 3,934 million, 4.5% more than the previous year.
Per share, Johnson & Johnson earned $ 1.44, which would amount to $ 2.05 if certain charges are excluded.
With these adjusted accounts, the company earned 5,590 million dollars, 7.3% more in year-on-year terms.
The chairman and CEO, Alex Gorsky, highlighted in a statement the growth of the company's pharmaceutical business and the progress in sales of consumer products and medical equipment.
Johnson & Johnson revised its forecasts slightly upwards for the whole year, which helped its price on Wall Street, where its shares rose today a clear 2.41% half an hour after the opening.